Myomo (MYO) Projected to Post Quarterly Earnings on Monday

Myomo (NYSEAMERICAN:MYO) is projected to post its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect Myomo to post earnings of ($0.09) per share and revenue of $10.4030 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 13, 2026 at 5:00 PM ET.

Myomo Stock Down 1.2%

Shares of NYSEAMERICAN:MYO opened at $0.78 on Monday. The firm has a fifty day moving average price of $0.89 and a two-hundred day moving average price of $0.94. The company has a market cap of $29.79 million, a price-to-earnings ratio of -2.67 and a beta of 1.17. The company has a debt-to-equity ratio of 0.17, a current ratio of 2.49 and a quick ratio of 2.10. Myomo has a one year low of $0.64 and a one year high of $6.30.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MYO. Dynamic Technology Lab Private Ltd purchased a new stake in Myomo during the first quarter valued at about $75,000. Invesco Ltd. bought a new position in shares of Myomo during the 2nd quarter valued at about $37,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Myomo during the 2nd quarter valued at about $38,000. Acadian Asset Management LLC purchased a new position in shares of Myomo during the 1st quarter valued at about $114,000. Finally, Engineers Gate Manager LP lifted its position in Myomo by 62.8% in the 2nd quarter. Engineers Gate Manager LP now owns 30,097 shares of the company’s stock worth $65,000 after buying an additional 11,614 shares during the last quarter. 44.99% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Ascendiant Capital Markets reduced their target price on Myomo from $10.50 to $10.00 and set a “buy” rating for the company in a research report on Friday, November 21st. Four investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Myomo currently has a consensus rating of “Buy” and a consensus target price of $7.67.

Myomo Company Profile

Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.

Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.